You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shafren D, Quah M, Wong Y, et al
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
Journal for ImmunoTherapy of Cancer 2014;2:P125. doi: 10.1186/2051-1426-2-S3-P125